氟哌啶醇与低效力的第一代抗精神病药物对精神分裂症。

文章的细节

引用

复制到剪贴板

迟缓的M, Huhn M, Kissling W,恩格尔RR, Leucht年代

氟哌啶醇与低效力的第一代抗精神病药物对精神分裂症。

科克伦数据库系统启2014 7月9;(7):CD009268。cd009268.pub2 doi: 10.1002/14651858.。

PubMed ID

25007358 (在PubMed

]

文摘

背景:抗精神病药物治疗精神分裂症的核心。治疗指南,没有抗精神病药物化合物之间的疗效差异,然而,低效力抗精神病药物临床上往往被视为比高效有效的化合物,他们似乎也有不同的副作用。目的:回顾氟哌啶醇的作用在临床反应和低效力抗精神病药物对精神分裂症患者。搜索方法:我们搜查了科克伦精神分裂症组试验注册(2010年7月)。选择标准:我们包括所有随机试验比较氟哌啶醇与第一代低效力抗精神病药物对精神分裂症患者的精神病或精神分裂。数据收集和分析:我们独立提取数据。对于两个数据,我们计算风险比率(RR)及其95%置信区间(CI)在意向性治疗基础上基于随机模型。对于连续数据,我们计算意味着差异(MD),基于随机模型。主要结果:回顾目前包括17个随机试验和877名参与者。包括研究的大小是16和109名参与者之间的关系。 All studies were short-term with a study length between two and 12 weeks. Overall, sequence generation, allocation procedures and blinding were poorly reported. We found no clear evidence that haloperidol was superior to low-potency antipsychotic drugs in terms of clinical response (haloperidol 40%, low-potency drug 36%, 14 RCTs, n = 574, RR 1.11, CI 0.86 to 1.44 lowquality evidence). There was also no clear evidence of benefit for either group in acceptability of treatment with equivocal difference in the number of participants leaving the studies early due to any reason (haloperidol 13%, low-potency antipsychotics 17%, 11 RCTs, n = 408, RR 0.82, CI 0.38 to 1.77, low quality evidence). Similar equivocal results were found between groups for experiencing at least one adverse effect (haloperidol 70%, low-potency antipsychotics 35%, 5 RCTs n = 158, RR 1.97, CI 0.69 to 5.66, very low quality evidence ). More participants from the low-potency drug group experienced sedation (haloperidol 14%, low-potency antipsychotics 41%, 2 RCTs, n = 44, RR 0.30, CI 0.11 to 0.82, moderate quality evidence), orthostasis problems (haloperidol 25%, low-potency antipsychotics 71%, 1 RCT, n = 41, RR 0.35, CI 0.16 to 0.78) and weight gain (haloperidol 5%, low-potency antipsychotics 29%, 3 RCTs, n = 88, RR 0.22, CI 0.06 to 0.81). In contrast, the outcome 'at least one movement disorder' was more frequent in the haloperidol group (haloperidol 72%, low-potency antipsychotics 41%, 5 RCTs, n = 170, RR 1.64, CI 1.22 to 2.21, low quality evidence). No data were available for death or quality of life. The results of the primary outcome were robust in several subgroup and sensitivity analyses. AUTHORS' CONCLUSIONS: The results do not clearly show a superiority in efficacy of haloperidol compared with low-potency antipsychotics. Differences in adverse events were found for movement disorders, which were more frequent in the haloperidol group, and orthostatic problems, sedation and weight gain, which were more frequent in the low-potency antipsychotic group. The quality of studies was low, and the quality of evidence for the main outcomes of interest varied from moderate to very low, so more newer studies would be needed in order to draw a definite conclusion about whether or not haloperidol is superior or inferior to low-potency antipsychotics.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

氟哌啶醇